Hong Kong makes belated bid to build biotech business

As Hong Kong belatedly wakes up to the benefits of biotechnology, Singapore streaks ahead.
September 29, 2000
More than a year after Singapore announced it would invest $1 billion to cultivate start-up biotechnology companies and make life sciences one of the main pillars of its economy, Hong Kong is finally taking action to catch up.

The government's Innovation and Technology Commission has put together a team headed by Sir Colin Dollery, senior consultant to SmithKline Beecham, to study Hong Kong's resources and make recommendations on how it can best take advantage of the genetic revolution.  

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Share our publication on social media
Share our publication on social media